Investigation into the pathophysiology of CLL allowed for the development of targeted agents, including Burton’s tyrosine kinase (BTK) inhibitors, anti-CD20 monoclonal antibody, and B-cell lymphoma 2 (BCL2) inhibitors[2]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.